奥泰生物拟1亿元至2亿元回购股份，公司股价年内涨7.56%

Core Viewpoint - Aotai Bio plans to repurchase shares through centralized bidding, with a total amount between 100 million and 200 million yuan, and a maximum repurchase price of 85.00 yuan per share, which is 23.69% higher than the current price of 68.72 yuan [1] Group 1: Company Overview - Aotai Bio, established on April 17, 2009, is located in Hangzhou, Zhejiang Province, and was listed on March 25, 2021 [1] - The company specializes in the research, production, and sales of in vitro diagnostic reagents, with revenue composition as follows: infectious diseases 42.27%, drug and substance abuse 26.74%, others 9.72%, women's health 8.81%, COVID-19 testing 6.60%, tumors 3.77%, myocardium 1.60%, and others 0.49% [1] Group 2: Financial Performance - As of October 31, Aotai Bio had 5,665 shareholders, a decrease of 1.29% from the previous period, with an average of 13,994 circulating shares per person, an increase of 1.31% [2] - For the period from January to September 2025, Aotai Bio achieved operating revenue of 633 million yuan, a year-on-year increase of 2.44%, while net profit attributable to the parent company was 190 million yuan, a decrease of 3.91% [2] Group 3: Shareholder Information - Aotai Bio has distributed a total of 1.28 billion yuan in dividends since its A-share listing, with 955.6 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the sixth largest shareholder with 2.1873 million shares, a decrease of 387,400 shares from the previous period, while Guotai Junan Value Advantage Flexible Allocation Mixed A (000362) entered as the ninth largest shareholder with 713,300 shares [3]